If Bollywood had a pharma category, Bliss GVS Pharma Ltd would win the “Best Supporting Suppository” award. Founded in 1984 and now trading at ₹128 per share (down -15.84% on Nov 7, 2025), this ₹1,352 crore market-cap company manufactures and exports everything from suppositories to syrups, mostly to the African market.
In the latest Q2FY26, the company reported Revenue of ₹244 crore and PAT of ₹27.2 crore, both up 12.3% YoY. That’s decent—but the real drama came off the spreadsheets. Managing Director Gagan Harsh Sharma resigned on Nov 6, 2025, right after an ESOP grant announcement. Coincidence? Maybe. Maybe not.
Margins have improved (EBITDA at ~20%), but Bliss GVS is still stuck in a low-growth zone — Sales growth (5 years): 3.27%. The company’s debt remains low at ₹88 crore, and a Debt-to-Equity ratio of just 0.08 means they could probably buy another factory in cash if they stopped issuing ESOPs for a minute.
So here’s the short version: margins up, leadership down, Africa strong, investors confused.
2. Introduction – The Suppository Empire Strikes Back
Bliss GVS Pharma is that rare company whose main claim to fame isn’t a tablet or capsule—but the humble suppository. Yes, the medicine that goes where most investors fear to tread. They’ve made it glamorous enough to dominate African markets.
Their flagship anti-malarial brand Lonart is WHO-endorsed and reportedly saving millions—while also paying the Mumbai electricity bill. ~94% of their FY24 revenue came from exports, and ~75% of that from sub-Saharan Africa. Basically, this Indian company’s profits depend on mosquito season in Nigeria.
But things haven’t been dull lately. Apart from MD exits and ESOP parties, Bliss has been busy expanding capacity (adding 200 million semi-solid units) and scaling its solar power (from 4.5 MW DC to 8.1 MW DC). They’re also in a mood to clean up—liquidating foreign subsidiaries and converting loans into equity.
Yet, with all this, revenue growth remains as sluggish as an old cough syrup. Still, they’ve managed to improve margins through cost cuts and logistics efficiency. The company’s ROCE sits at 11.7% and ROE at 8.36%—modest, but acceptable in pharma land.
And let’s not forget, their Africa playbook is still unbeatable. While Indian peers chase USFDA dreams, Bliss quietly dominates suppository shelves in Ghana and Nigeria.
3. Business Model – WTF Do They Even Do?
Let’s decode it in plain English. Bliss GVS Pharma makes pharmaceutical formulations—mostly suppositories, pessaries, capsules, tablets, and syrups. The company operates across 60+ therapeutic segments: anti-malarial, anti-fungal, anti-bacterial, antibiotic, contraceptive—you name it, they’ve packed it into some shape or form.
Their real money-spinner? Suppositories and pessaries. It’s a niche, but a profitable one. They’re the first Indian EU-GMP-certified manufacturer of this dosage form and one of the global leaders in it.
They have 7 manufacturing units, including two in Nigeria, producing:
680 million tablets
380 million suppositories/pessaries
180 million capsules
90 million ointments and gels
206 million lozenges
64 million skincare products
30 million dry syrups
They also contract manufacture for pharma biggies like Sun Pharma, Alkem, Mankind, and Sanofi, but with a catch: these Indian giants can’t export Bliss’s products. Bliss keeps the export pie to itself—smart, right?
Their flagship brand Lonart dominates Africa’s malaria-fighting market. It’s a strong moat—but also a dependency risk.
4. Financials Overview – The Quarter with a Twist
Consolidated Quarterly Financials (₹ crore)
Metric
Q2FY26 (Sep 2025)
Q2FY25 (Sep 2024)
Q1FY26 (Jun 2025)
YoY %
QoQ %
Revenue
244
218
207
+12.3%
+17.9%
EBITDA
49
41
41
+19.5%
0.0%
PAT
27.2
24.3
44
+12.3%
-38.2%
EPS (₹)
2.58
2.31
4.08
+12.3%
-36.7%
EBITDA margin is hovering around 20%, which is impressive given the rising raw material costs.
But the PAT dip QoQ (-38%) screams “one-time income hangover.” Remember that ₹83 crore other income last year? Yep. That ghost is still haunting comparisons.
P/E at 12.3x looks “cheap,” but when growth is 3%, it’s less “undervalued” and more “underdelivering.”
5. Valuation Discussion – Fair Value Range Only
Let’s crunch numbers the Edu way (not the YouTube thumbnail way).
EPS (TTM) = ₹10.4
P/E Range (Industry median 32.8x)
Conservative: 10x → ₹104
Optimistic: 20x → ₹208
Fair Value Range by P/E: ₹104 – ₹208
EV/EBITDA = 5.93
Apply sector average 12–15x → ₹1,227 Cr * (12/5.93) → fair EV ~₹2,483 Cr – ₹3,108 Cr
Market cap corresponding = ₹2,500 – ₹3,100 Cr
Per share fair range (10.6 Cr shares): ₹236 – ₹293
